Good News SR-9009 users

[Maxadvance]

Looks like taking massive doses of the stuff reduces plaque in the arteries of mice. Hopefully smaller amounts can be beneficial too.

http://www.ncbi.nlm.nih.gov/pubmed/25800870

Suppression of atherosclerosis by synthetic REV-ERB agonist.
Sitaula S1, Billon C2, Kamenecka TM1, Solt LA1, Burris TP3.
Author information
Abstract
The nuclear receptors for heme, REV-ERBα and REV-ERBβ, play important roles in the regulation of metabolism and inflammation. Recently it was demonstrated that reduced REV-ERBα expression in hematopoetic cells in LDL receptor null mice led to increased atherosclerosis. We sought to determine if synthetic REV-ERB agonists that we have developed might have the ability to suppress atherosclerosis in this model. A previously characterized synthetic REV-ERB agonist, SR9009, was used to determine if activation of REV-ERB activity would affect atherosclerosis in LDL receptor deficient mice. Atherosclerotic plaque size was significantly reduced (p < 0.05) in mice administered SR9009 (100 mg/kg) for seven weeks compared to control mice (n = 10 per group). SR9009 treatment of bone marrow-derived mouse macrophages (BMDM) reduced the polarization of BMDMs to proinflammatory M1 macrophage while increasing the polarization of BMDMs to anti-inflammatory M2 macrophages. Our results suggest that pharmacological targeting of REV-ERBs may be a viable therapeutic option for treatment of atherosclerosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

 

[DylanGemelli]

Looks like taking massive doses of the stuff reduces plaque in the arteries of mice. Hopefully smaller amounts can be beneficial too.

http://www.ncbi.nlm.nih.gov/pubmed/25800870

Suppression of atherosclerosis by synthetic REV-ERB agonist.
Sitaula S1, Billon C2, Kamenecka TM1, Solt LA1, Burris TP3.
Author information
Abstract
The nuclear receptors for heme, REV-ERBα and REV-ERBβ, play important roles in the regulation of metabolism and inflammation. Recently it was demonstrated that reduced REV-ERBα expression in hematopoetic cells in LDL receptor null mice led to increased atherosclerosis. We sought to determine if synthetic REV-ERB agonists that we have developed might have the ability to suppress atherosclerosis in this model. A previously characterized synthetic REV-ERB agonist, SR9009, was used to determine if activation of REV-ERB activity would affect atherosclerosis in LDL receptor deficient mice. Atherosclerotic plaque size was significantly reduced (p < 0.05) in mice administered SR9009 (100 mg/kg) for seven weeks compared to control mice (n = 10 per group). SR9009 treatment of bone marrow-derived mouse macrophages (BMDM) reduced the polarization of BMDMs to proinflammatory M1 macrophage while increasing the polarization of BMDMs to anti-inflammatory M2 macrophages. Our results suggest that pharmacological targeting of REV-ERBs may be a viable therapeutic option for treatment of atherosclerosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

NICE BROTHER! that's HUGE if it is shown to work on humans... just knowing their is a chance or probability of that is extremely exciting! Thanks for posting!

 

[Maxadvance]

NICE BROTHER! that's HUGE if it is shown to work on humans... just knowing their is a chance or probability of that is extremely exciting! Thanks for posting!

It would be huge, reverses arterial plaque and suppresses inflammation caused by LDL, potential to save lives and improve blood lipids, that's good stuff

 

[DylanGemelli]

It would be huge, reverses arterial plaque and suppresses inflammation caused by LDL, potential to save lives and improve blood lipids, that's good stuff

absolutely... what that could do for people is extremely exciting... i hope this pursued further and more studies are done... you just never know the way politics are amongst other drug companies etc... they have a lot of money to throw around and tend to do whatever it takes to ensure business stays at the top and unfortunately, that comes at the expense of many other innocent people...

 

[RickRock]

Looks like taking massive doses of the stuff reduces plaque in the arteries of mice. Hopefully smaller amounts can be beneficial too.

http://www.ncbi.nlm.nih.gov/pubmed/25800870

Suppression of atherosclerosis by synthetic REV-ERB agonist.
Sitaula S1, Billon C2, Kamenecka TM1, Solt LA1, Burris TP3.
Author information
Abstract
The nuclear receptors for heme, REV-ERBα and REV-ERBβ, play important roles in the regulation of metabolism and inflammation. Recently it was demonstrated that reduced REV-ERBα expression in hematopoetic cells in LDL receptor null mice led to increased atherosclerosis. We sought to determine if synthetic REV-ERB agonists that we have developed might have the ability to suppress atherosclerosis in this model. A previously characterized synthetic REV-ERB agonist, SR9009, was used to determine if activation of REV-ERB activity would affect atherosclerosis in LDL receptor deficient mice. Atherosclerotic plaque size was significantly reduced (p < 0.05) in mice administered SR9009 (100 mg/kg) for seven weeks compared to control mice (n = 10 per group). SR9009 treatment of bone marrow-derived mouse macrophages (BMDM) reduced the polarization of BMDMs to proinflammatory M1 macrophage while increasing the polarization of BMDMs to anti-inflammatory M2 macrophages. Our results suggest that pharmacological targeting of REV-ERBs may be a viable therapeutic option for treatment of atherosclerosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Wow man. It's nice seeing these type of benefits. I know that the dose is ridiculously high, and not everything translates to humans the same, but he potential is there for one VERY GOOD benefit from SR9009. Thanks for sharing bro